NASDAQ · SKIN

SkinHealth Systems Inc.

Healthcare · Medical - Specialties

$0.70▲ 1.45% ($0.01)at close

As of 4:00 PM ET

52-week

$0.55$2.69

Market cap

$90.72M

P/E

What the market price implies · Reverse DCF

To support a price of $0.70, this model requires revenue to grow by 1.29%/yr over the next 10 years, compounded annually.

Historical revenue grew by 3.7%/yr over the past 4 years. The required annual growth rate is 2.41 percentage points lower.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

1.29%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$0.70

Estimated value / share

$0.64

Base scenario

This estimate is 8.47% below the price used.

USD · TTM ending 2026-06-30

Year 1 growth 0% · Ending margin 0% · Discount rate 6.97%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 11, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 11:18 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -71.66%Revenue (TTM): -6.46%FCF (TTM): -54.38%P/FCF: 30th pct

What changed

The stock fell 71.66% over the last year. Revenue declined 6.46% over the trailing twelve months. Operating margin moved from -14% to -1.49%. Free cash flow declined 54.38% over the trailing twelve months.

What the market seems to be pricing

The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/FCF, investors are still discounting lower future earnings power.

What would invalidate this read

Operating margin stands at -1.49%. Revenue declined 6.46% — this read reverses if that trend stabilizes. Free cash flow fell 54.38% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America.

CEOPedro Malha

SectorHealthcare

IndustryMedical - Specialties

Employees613

IPO dateNov 24, 2020

https://www.skinhealthsystems.com

Market multiples

Forward P/E—

EV/EBITDA8.30

Enterprise value$321.67M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-7.77%

Gross margin (FY2025)65.28%▲10.8ppvs FY2024

Operating margin (FY2025)-6.92%▲13.4ppvs FY2024

ROE-43.83%▼27.0ppvs FY2025

Analyst consensus

RatingHold

Target price$1.50▲114.29%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.07 · Revenue est $67.83M

View